Integra (NASDAQ: IART) EVP gets 43,350 RSUs, shares withheld for tax

Rhea-AI Filing Summary

Integra LifeSciences executive Robert T. Davis Jr., EVP & President, TT, received a grant of 43,350 restricted stock units on March 11, 2026. These RSUs vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date.

To cover tax obligations, 8,487 shares of common stock were disposed of at $9.61 per share on March 11, 2026, and 687 shares at $9.55 per share on March 10, 2026, both classified as tax-withholding transactions rather than open-market sales. After these transactions, Davis directly holds 66,387 shares of common stock and 43,350 RSUs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DAVIS ROBERT T. JR.

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & President, TT

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		F		687	D	$9.55	74,874	D
Common Stock	03/11/2026		F		8,487	D	$9.61	66,387	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/11/2026		A		43,350		(1)	(1)	Common Stock	43,350	$0	43,350	D

Explanation of Responses:

1. The award was a restricted stock unit award which will vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date of 3/11/2026.

Remarks:

	/s/ Michael D. Hutchinson; Attorney-in-Fact for Robert T. Davis	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity award did Integra LifeSciences (IART) executive Robert T. Davis Jr. receive?

Robert T. Davis Jr. received a grant of 43,350 restricted stock units (RSUs). The award vests 33% on the first and second anniversaries and 34% on the third anniversary of the March 11, 2026 grant date, providing multi-year equity-based compensation.

How do the new RSUs for Integra (IART) executive Robert Davis Jr. vest over time?

The 43,350 RSUs vest in three tranches: 33% on the first anniversary, 33% on the second, and 34% on the third anniversary of the March 11, 2026 grant date. This schedule encourages long-term retention and alignment with shareholder interests.

Were Integra (IART) shares sold on the market in this Form 4 for Robert Davis Jr.?

No open-market sales are reported. Two transactions labeled code F show 8,487 shares at $9.61 and 687 shares at $9.55 disposed to satisfy tax liabilities, meaning shares were withheld rather than actively sold into the market.

How many Integra LifeSciences (IART) shares does Robert T. Davis Jr. hold after these transactions?

Following the reported transactions, Robert T. Davis Jr. directly holds 66,387 shares of Integra common stock. He also has a separate position of 43,350 restricted stock units that convert into common shares as they vest over the next three years.

What is transaction code F in the Integra (IART) Form 4 for Robert Davis Jr.?

Transaction code F represents shares withheld or delivered to pay exercise price or tax liabilities. In this case, a total of 9,174 shares of common stock were used to cover tax obligations tied to equity compensation, not discretionary market sales.